You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameValsartan
Accession NumberDB00177  (APRD00133)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionValsartan is an angiotensin-receptor blocker (ARB) that may be used to treat a variety of cardiac conditions including hypertension, diabetic nephropathy and heart failure. Valsartan lowers blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); it competes with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents the blood pressure increasing effects of angiotensin II. Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs do not have the adverse effect of dry cough. Valsartan may be used to treat hypertension, isolated systolic hypertension, left ventricular hypertrophy and diabetic nephropathy. It may also be used as an alternative agent for the treatment of heart failure, systolic dysfunction, myocardial infarction and coronary artery disease.
Structure
Thumb
Synonyms
(S)-N-Valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine
Diovan
N-(P-(O-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine
N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act ValsartanTablet320 mgOralActavis Pharma Company2011-02-16Not applicableCanada
Act ValsartanTablet40 mgOralActavis Pharma Company2011-02-16Not applicableCanada
Act ValsartanTablet80 mgOralActavis Pharma Company2011-02-16Not applicableCanada
Act ValsartanTablet160 mgOralActavis Pharma Company2011-02-16Not applicableCanada
Auro-valsartanTablet160 mgOralAuro Pharma Inc2014-02-06Not applicableCanada
Auro-valsartanTablet40 mgOralAuro Pharma Inc2014-02-06Not applicableCanada
Auro-valsartanTablet320 mgOralAuro Pharma Inc2014-02-06Not applicableCanada
Auro-valsartanTablet80 mgOralAuro Pharma Inc2014-02-06Not applicableCanada
Ava-valsartanTablet320 mgOralAvanstra Inc2011-08-182014-08-21Canada
Ava-valsartanTablet40 mgOralAvanstra Inc2011-08-182014-08-21Canada
Ava-valsartanTablet80 mgOralAvanstra Inc2011-08-182014-08-21Canada
Ava-valsartanTablet160 mgOralAvanstra Inc2011-08-182014-08-21Canada
DiovanTablet320 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-28Not applicableUs
DiovanTablet160 mg/1OralPd Rx Pharmaceuticals, Inc.2001-07-01Not applicableUs
DiovanTablet80 mg/1OralCarilion Materials Management2001-07-01Not applicableUs
DiovanTablet320 mg/1OralPhysicians Total Care, Inc.2007-09-17Not applicableUs
DiovanTablet160 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-28Not applicableUs
DiovanTablet80 mg/1OralNovartis Pharmaceuticals Corporation2001-07-01Not applicableUs
DiovanTablet160 mg/1Oralbryant ranch prepack2001-07-01Not applicableUs
DiovanTablet320 mgOralNovartis Pharmaceuticals Canada Inc2007-02-14Not applicableCanada
DiovanTablet80 mg/1OralRebel Distributors Corp2001-07-01Not applicableUs
DiovanTablet80 mg/1OralREMEDYREPACK INC.2014-01-092016-10-13Us
DiovanTablet80 mg/1OralPd Rx Pharmaceuticals, Inc.2001-07-01Not applicableUs
DiovanTablet40 mg/1OralCarilion Materials Management2001-07-01Not applicableUs
DiovanTablet40 mg/1OralPhysicians Total Care, Inc.2009-01-02Not applicableUs
DiovanTablet80 mg/1OralAphena Pharma Solutions Tennessee, Llc2001-07-01Not applicableUs
DiovanTablet80 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-28Not applicableUs
DiovanTablet160 mg/1OralNovartis Pharmaceuticals Corporation2001-07-01Not applicableUs
DiovanTablet160 mg/1OralCardinal Health2001-07-01Not applicableUs
DiovanTablet160 mg/1OralRebel Distributors Corp2001-07-01Not applicableUs
DiovanTablet320 mg/1OralA S Medication Solutions2001-07-01Not applicableUs
DiovanTablet160 mg/1OralREMEDYREPACK INC.2013-09-112016-11-30Us
DiovanTablet320 mg/1OralPd Rx Pharmaceuticals, Inc.2001-07-01Not applicableUs
DiovanTablet80 mg/1OralCardinal Health2001-07-01Not applicableUs
DiovanTablet160 mg/1OralAphena Pharma Solutions Tennessee, Llc2001-07-01Not applicableUs
DiovanTablet160 mg/1OralPhysicians Total Care, Inc.2008-02-28Not applicableUs
DiovanTablet320 mg/1OralNovartis Pharmaceuticals Corporation2001-07-01Not applicableUs
DiovanTablet320 mg/1OralCardinal Health2001-07-01Not applicableUs
DiovanTablet320 mg/1OralRebel Distributors Corp2001-07-01Not applicableUs
DiovanTablet40 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-15Not applicableUs
DiovanTablet80 mg/1Oralbryant ranch prepack2001-07-01Not applicableUs
DiovanTablet40 mgOralNovartis Pharmaceuticals Canada Inc2005-11-01Not applicableCanada
DiovanTablet80 mg/1OralPhysicians Total Care, Inc.2010-01-06Not applicableUs
DiovanTablet40 mg/1OralNovartis Pharmaceuticals Corporation2001-07-01Not applicableUs
Diovan 160mgCapsule160 mgOralNovartis Pharmaceuticals Canada Inc1997-12-15Not applicableCanada
Diovan 160mg TabletsTablet160 mgOralNovartis Pharmaceuticals Canada Inc2003-01-24Not applicableCanada
Diovan 80mgCapsule80 mgOralNovartis Pharmaceuticals Canada Inc1997-12-15Not applicableCanada
Diovan 80mg TabletsTablet80 mgOralNovartis Pharmaceuticals Canada Inc2003-01-24Not applicableCanada
Dom-valsartanTablet40 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-valsartanTablet80 mgOralDominion Pharmacal2014-02-03Not applicableCanada
Dom-valsartanTablet160 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-valsartanTablet320 mgOralDominion PharmacalNot applicableNot applicableCanada
Mylan-valsartanTablet160 mgOralMylan Pharmaceuticals Ulc2012-04-27Not applicableCanada
Mylan-valsartanTablet320 mgOralMylan Pharmaceuticals Ulc2012-04-27Not applicableCanada
Mylan-valsartanTablet40 mgOralMylan Pharmaceuticals Ulc2012-04-27Not applicableCanada
Mylan-valsartanTablet80 mgOralMylan Pharmaceuticals Ulc2012-04-27Not applicableCanada
Novo-valsartanTablet40 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Novo-valsartanTablet80 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Novo-valsartanTablet160 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Novo-valsartanTablet320 mgOralTeva Canada LimitedNot applicableNot applicableCanada
PMS-valsartanTablet160 mgOralPharmascience Inc2012-05-22Not applicableCanada
PMS-valsartanTablet320 mgOralPharmascience Inc2012-05-22Not applicableCanada
PMS-valsartanTablet40 mgOralPharmascience Inc2012-05-22Not applicableCanada
PMS-valsartanTablet80 mgOralPharmascience Inc2012-05-22Not applicableCanada
Q-valsartanTablet40 mgOralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-valsartanTablet80 mgOralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-valsartanTablet160 mgOralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-valsartanTablet320 mgOralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Ran-valsartanTablet80 mgOralRanbaxy Pharmaceuticals Canada Inc.2011-02-16Not applicableCanada
Ran-valsartanTablet160 mgOralRanbaxy Pharmaceuticals Canada Inc.2011-02-16Not applicableCanada
Ran-valsartanTablet40 mgOralRanbaxy Pharmaceuticals Canada Inc.2011-02-16Not applicableCanada
Riva-valsartanTablet40 mgOralLaboratoire Riva Inc2014-12-03Not applicableCanada
Riva-valsartanTablet80 mgOralLaboratoire Riva Inc2014-12-03Not applicableCanada
Riva-valsartanTablet160 mgOralLaboratoire Riva Inc2014-12-03Not applicableCanada
Riva-valsartanTablet320 mgOralLaboratoire Riva Inc2014-12-03Not applicableCanada
Sandoz ValsartanTablet160 mgOralSandoz Canada Incorporated2011-01-27Not applicableCanada
Sandoz ValsartanTablet320 mgOralSandoz Canada Incorporated2011-01-27Not applicableCanada
Sandoz ValsartanTablet40 mgOralSandoz Canada Incorporated2011-01-27Not applicableCanada
Sandoz ValsartanTablet80 mgOralSandoz Canada Incorporated2011-01-27Not applicableCanada
Teva-valsartanTablet160 mgOralTeva Canada Limited2011-02-16Not applicableCanada
Teva-valsartanTablet320 mgOralTeva Canada Limited2011-02-16Not applicableCanada
Teva-valsartanTablet40 mgOralTeva Canada Limited2011-02-16Not applicableCanada
Teva-valsartanTablet80 mgOralTeva Canada Limited2011-02-16Not applicableCanada
ValsartanTablet80 mgOralSivem Pharmaceuticals Ulc2012-06-10Not applicableCanada
ValsartanTablet40 mgOralActavis Pharma CompanyNot applicableNot applicableCanada
ValsartanTablet160 mgOralPro Doc Limitee2011-05-30Not applicableCanada
ValsartanTablet40 mg/1OralSandoz Inc2014-07-07Not applicableUs
ValsartanTablet160 mgOralSanis Health Inc2012-07-20Not applicableCanada
ValsartanTablet80 mg/1OralCardinal Health2014-07-07Not applicableUs
ValsartanTablet320 mg/1OralAphena Pharma Solutions Tennessee, Llc2014-07-07Not applicableUs
ValsartanTablet160 mgOralSivem Pharmaceuticals Ulc2012-06-10Not applicableCanada
ValsartanTablet160 mgOralActavis Pharma CompanyNot applicableNot applicableCanada
ValsartanTablet320 mgOralPro Doc Limitee2011-05-30Not applicableCanada
ValsartanTablet40 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
ValsartanTablet80 mg/1OralSandoz Inc2014-07-07Not applicableUs
ValsartanTablet320 mgOralSanis Health Inc2012-07-20Not applicableCanada
ValsartanTablet320 mgOralSivem Pharmaceuticals Ulc2012-06-10Not applicableCanada
ValsartanTablet80 mgOralActavis Pharma CompanyNot applicableNot applicableCanada
ValsartanTablet40 mgOralSanis Health Inc2012-07-20Not applicableCanada
ValsartanTablet80 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
ValsartanTablet160 mg/1OralSandoz Inc2014-07-07Not applicableUs
ValsartanTablet160 mg/1OralAphena Pharma Solutions Tennessee, Llc2014-07-07Not applicableUs
ValsartanTablet40 mgOralPro Doc Limitee2011-05-30Not applicableCanada
ValsartanTablet40 mgOralSivem Pharmaceuticals Ulc2012-06-10Not applicableCanada
ValsartanTablet320 mgOralActavis Pharma CompanyNot applicableNot applicableCanada
ValsartanTablet80 mgOralSanis Health Inc2012-07-20Not applicableCanada
ValsartanTablet160 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
ValsartanTablet320 mg/1OralSandoz Inc2014-07-07Not applicableUs
ValsartanTablet80 mg/1OralAphena Pharma Solutions Tennessee, Llc2014-07-07Not applicableUs
ValsartanTablet160 mg/1OralCardinal Health2014-07-07Not applicableUs
ValsartanTablet80 mgOralPro Doc Limitee2011-05-30Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-valsartanTablet40 mgOralApotex Inc2012-07-12Not applicableCanada
Apo-valsartanTablet80 mgOralApotex Inc2012-07-12Not applicableCanada
Apo-valsartanTablet160 mgOralApotex Inc2012-07-12Not applicableCanada
Apo-valsartanTablet320 mgOralApotex Inc2012-07-12Not applicableCanada
ValsartanTablet, film coated40 mg/1OralAv Pak2016-06-29Not applicableUs
ValsartanTablet, film coated320 mg/1OralMylan Pharmaceuticals Inc.2015-01-05Not applicableUs
ValsartanTablet, film coated320 mg/1OralA S Medication Solutions2015-01-05Not applicableUs
ValsartanTablet, film coated160 mg/1OralAv Kare, Inc.2015-11-12Not applicableUs
ValsartanTablet, film coated160 mg/1OralNorthwind Pharmaceuticals2015-01-07Not applicableUs
ValsartanTablet80 mg/1OralLupin Pharmaceuticals, Inc.2015-01-05Not applicableUs
ValsartanTablet40 mg/1OralJubilant Cadista Pharmaceuticals Inc.2014-12-23Not applicableUs
ValsartanTablet, film coated40 mg/1OralMacleods Pharmaceuticals Limited2016-08-29Not applicableUs
ValsartanTablet, film coated40 mg/1OralTeva Pharmaceuticals USA Inc2015-01-05Not applicableUs
ValsartanTablet, film coated80 mg/1OralREMEDYREPACK INC.2016-07-25Not applicableUs
ValsartanTablet320 mg/1OralTorrent Pharmaceuticals Limited2015-01-05Not applicableUs
ValsartanTablet160 mg/1OralSolco Healthcare US, LLC2015-08-31Not applicableUs
ValsartanTablet, film coated80 mg/1OralAmerican Health Packaging2015-02-20Not applicableUs
ValsartanTablet320 mg/1OralProficient Rx LP2015-08-31Not applicableUs
ValsartanTablet40 mg/1OralAmneal Pharmaceuticals of New York, LLC2016-01-17Not applicableUs
ValsartanTablet, film coated40 mg/1OralLucid Pharma Llc2015-01-05Not applicableUs
ValsartanTablet, film coated320 mg/1OralActavis Pharma, Inc.2015-01-05Not applicableUs
ValsartanTablet320 mg/1OralA S Medication Solutions2015-01-062017-04-30Us
ValsartanTablet, film coated160 mg/1OralAv Kare, Inc.2015-01-29Not applicableUs
ValsartanTablet, film coated320 mg/1OralOhm Laboratories Inc.2014-07-07Not applicableUs
ValsartanTablet160 mg/1OralAlembic Pharmaceuticals Limited2015-01-06Not applicableUs
ValsartanTablet, film coated160 mg/1OralAurobindo Pharma Limited2015-01-05Not applicableUs
ValsartanTablet80 mg/1OralQualitest Pharmaceuticals2015-01-062017-08-31Us
ValsartanTablet, film coated320 mg/1OralAphena Pharma Solutions Tennessee, Llc2014-07-07Not applicableUs
ValsartanTablet, film coated40 mg/1OralMylan Pharmaceuticals Inc.2015-01-05Not applicableUs
ValsartanTablet80 mg/1OralAlembic Pharmaceuticals Inc.2016-05-20Not applicableUs
ValsartanTablet, film coated320 mg/1OralCamber Pharmaceuticals, Inc.2015-01-05Not applicableUs
ValsartanTablet, film coated80 mg/1OralAv Pak2016-06-29Not applicableUs
ValsartanTablet, film coated40 mg/1OralActavis Pharma, Inc.2015-01-05Not applicableUs
ValsartanTablet, film coated320 mg/1OralA S Medication Solutions2015-01-05Not applicableUs
ValsartanTablet, film coated320 mg/1OralAv Kare, Inc.2015-11-12Not applicableUs
ValsartanTablet, film coated40 mg/1OralOhm Laboratories Inc.2014-07-07Not applicableUs
ValsartanTablet160 mg/1OralLupin Pharmaceuticals, Inc.2015-01-05Not applicableUs
ValsartanTablet80 mg/1OralJubilant Cadista Pharmaceuticals Inc.2014-12-23Not applicableUs
ValsartanTablet, film coated80 mg/1OralMacleods Pharmaceuticals Limited2016-08-29Not applicableUs
ValsartanTablet, film coated80 mg/1OralTeva Pharmaceuticals USA Inc2015-01-05Not applicableUs
ValsartanTablet, film coated160 mg/1OralREMEDYREPACK INC.2016-07-25Not applicableUs
ValsartanTablet, film coated40 mg/1OralCamber Pharmaceuticals, Inc.2015-01-05Not applicableUs
ValsartanTablet320 mg/1OralSolco Healthcare US, LLC2015-08-31Not applicableUs
ValsartanTablet, film coated160 mg/1OralAmerican Health Packaging2015-02-20Not applicableUs
ValsartanTablet320 mg/1OralLake Erie Medical DBA Quality Care Products LLC2015-08-31Not applicableUs
ValsartanTablet, film coated160 mg/1OralPhysicians Total Care, Inc.2015-01-05Not applicableUs
ValsartanTablet80 mg/1OralAmneal Pharmaceuticals of New York, LLC2016-01-17Not applicableUs
ValsartanTablet, film coated80 mg/1OralLucid Pharma Llc2015-01-05Not applicableUs
ValsartanTablet40 mg/1OralTorrent Pharmaceuticals Limited2015-01-05Not applicableUs
ValsartanTablet, film coated160 mg/1OralA S Medication Solutions2015-01-05Not applicableUs
ValsartanTablet, film coated320 mg/1OralAv Kare, Inc.2015-01-29Not applicableUs
ValsartanTablet320 mg/1OralAlembic Pharmaceuticals Limited2015-01-06Not applicableUs
ValsartanTablet, film coated320 mg/1OralAurobindo Pharma Limited2015-01-05Not applicableUs
ValsartanTablet160 mg/1OralQualitest Pharmaceuticals2015-01-062017-08-31Us
ValsartanTablet80 mg/1OralA S Medication Solutions2015-01-05Not applicableUs
ValsartanTablet, film coated80 mg/1OralMylan Pharmaceuticals Inc.2015-01-05Not applicableUs
ValsartanTablet160 mg/1OralAlembic Pharmaceuticals Inc.2016-05-20Not applicableUs
ValsartanTablet, film coated40 mg/1OralAv Kare, Inc.2015-11-12Not applicableUs
ValsartanTablet, film coated160 mg/1OralAv Pak2016-06-29Not applicableUs
ValsartanTablet, film coated80 mg/1OralActavis Pharma, Inc.2015-01-05Not applicableUs
ValsartanTablet160 mg/1OralA S Medication Solutions2015-01-062017-08-31Us
ValsartanTablet, film coated40 mg/1OralAv Kare, Inc.2015-01-29Not applicableUs
ValsartanTablet, film coated80 mg/1OralOhm Laboratories Inc.2014-07-07Not applicableUs
ValsartanTablet320 mg/1OralLupin Pharmaceuticals, Inc.2015-01-05Not applicableUs
ValsartanTablet160 mg/1OralJubilant Cadista Pharmaceuticals Inc.2014-12-23Not applicableUs
ValsartanTablet, film coated160 mg/1OralMacleods Pharmaceuticals Limited2016-08-29Not applicableUs
ValsartanTablet, film coated160 mg/1OralTeva Pharmaceuticals USA Inc2015-01-05Not applicableUs
ValsartanTablet, film coated320 mg/1OralREMEDYREPACK INC.2016-07-25Not applicableUs
ValsartanTablet, film coated80 mg/1OralCamber Pharmaceuticals, Inc.2015-01-05Not applicableUs
ValsartanTablet40 mg/1OralAlembic Pharmaceuticals Limited2015-01-06Not applicableUs
ValsartanTablet, film coated40 mg/1OralAurobindo Pharma Limited2015-01-05Not applicableUs
ValsartanTablet160 mg/1OralLake Erie Medical DBA Quality Care Products LLC2015-08-31Not applicableUs
ValsartanTablet, film coated320 mg/1OralPhysicians Total Care, Inc.2015-01-05Not applicableUs
ValsartanTablet160 mg/1OralAmneal Pharmaceuticals of New York, LLC2016-01-17Not applicableUs
ValsartanTablet, film coated160 mg/1OralLucid Pharma Llc2015-01-05Not applicableUs
ValsartanTablet80 mg/1OralTorrent Pharmaceuticals Limited2015-01-05Not applicableUs
ValsartanTablet80 mg/1OralA S Medication Solutions2015-08-31Not applicableUs
ValsartanTablet40 mg/1OralSolco Healthcare US, LLC2015-08-31Not applicableUs
ValsartanTablet, film coated80 mg/1OralAv Kare, Inc.2015-11-12Not applicableUs
ValsartanTablet, film coated80 mg/1OralNorthwind Pharmaceuticals, LLC2014-11-13Not applicableUs
ValsartanTablet40 mg/1OralLupin Pharmaceuticals, Inc.2015-01-05Not applicableUs
ValsartanTablet320 mg/1OralQualitest Pharmaceuticals2015-01-062017-04-30Us
ValsartanTablet320 mg/1OralA S Medication Solutions2015-01-05Not applicableUs
ValsartanTablet, film coated160 mg/1OralMylan Pharmaceuticals Inc.2015-01-05Not applicableUs
ValsartanTablet320 mg/1OralAlembic Pharmaceuticals Inc.2016-05-20Not applicableUs
ValsartanTablet, film coated320 mg/1OralAv Pak2016-06-29Not applicableUs
ValsartanTablet, film coated160 mg/1OralActavis Pharma, Inc.2015-01-05Not applicableUs
ValsartanTablet80 mg/1OralA S Medication Solutions2015-01-062017-08-31Us
ValsartanTablet, film coated80 mg/1OralAv Kare, Inc.2015-01-29Not applicableUs
ValsartanTablet, film coated160 mg/1OralOhm Laboratories Inc.2014-07-07Not applicableUs
ValsartanTablet, film coated80 mg/1OralAvera Mc Kennan Hospital2015-05-20Not applicableUs
ValsartanTablet320 mg/1OralJubilant Cadista Pharmaceuticals Inc.2014-12-23Not applicableUs
ValsartanTablet40 mg/1OralQualitest Pharmaceuticals2015-01-062016-10-31Us
ValsartanTablet, film coated320 mg/1OralMacleods Pharmaceuticals Limited2016-08-29Not applicableUs
ValsartanTablet, film coated320 mg/1OralTeva Pharmaceuticals USA Inc2015-01-052016-10-31Us
ValsartanTablet40 mg/1OralAlembic Pharmaceuticals Inc.2016-05-20Not applicableUs
ValsartanTablet, film coated160 mg/1OralCamber Pharmaceuticals, Inc.2015-01-05Not applicableUs
ValsartanTablet80 mg/1OralAlembic Pharmaceuticals Limited2015-01-06Not applicableUs
ValsartanTablet, film coated80 mg/1OralAurobindo Pharma Limited2015-01-05Not applicableUs
ValsartanTablet80 mg/1OralSolco Healthcare US, LLC2015-08-31Not applicableUs
ValsartanTablet, film coated80 mg/1OralPhysicians Total Care, Inc.2015-01-05Not applicableUs
ValsartanTablet320 mg/1OralAmneal Pharmaceuticals of New York, LLC2016-01-17Not applicableUs
ValsartanTablet, film coated320 mg/1OralLucid Pharma Llc2015-01-05Not applicableUs
ValsartanTablet160 mg/1OralTorrent Pharmaceuticals Limited2015-01-05Not applicableUs
ValsartanTablet, film coated160 mg/1OralPreferred Pharmaceuticals, Inc.2016-11-08Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
Amlodipine and ValsartanSandoz Inc
Amlodipine, Valsartan and HydrochlorothiazideTorrent Pharmaceuticals Limited
Amlodipine, Valsartan, and HydrochlorothiazideTeva Pharmaceuticals USA Inc
Amlodipine, Valsartan, HydrochlorothiazideSandoz Inc
Apo-valsartan/hctzApotex Inc
Auro-valsartan HctAuro Pharma Inc
Ava-valsartan HctAvanstra Inc
ByvalsonAllergan, Inc
DafiroNovartis Europharm Ltd.
Diovan HctNovartis Pharmaceuticals Corporation
Diovan-hctNovartis Pharmaceuticals Canada Inc
EntrestoNovartis Pharmaceuticals Corporation
ExforgeNovartis Pharmaceuticals Corporation
Exforge HctNovartis Pharmaceuticals Corporation
ImpridaNovartis Europharm Ltd
Imprida HctNovartis Europharm Ltd.
Mylan-valsartan HctzMylan Pharmaceuticals Ulc
Novo-valsartan/hctzTeva Canada Limited
PMS-valsartan-hctzPharmascience Inc
Q-valsartan HctzQd Pharmaceuticals Ulc
Sandoz Valsartan HctSandoz Canada Incorporated
Teva-valsartan/hctzTeva Canada Limited
Valsartan and HydrochlorothiazideMylan Pharmaceuticals Inc.
Valsartan HctSanis Health Inc
Valsartan HctzNorthwind Pharmaceuticals
Valsartan-hctzPro Doc Limitee
SaltsNot Available
Categories
UNII80M03YXJ7I
CAS number137862-53-4
WeightAverage: 435.5188
Monoisotopic: 435.227039819
Chemical FormulaC24H29N5O3
InChI KeyACWBQPMHZXGDFX-QFIPXVFZSA-N
InChI
InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1
IUPAC Name
(2S)-3-methyl-2-[N-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)pentanamido]butanoic acid
SMILES
CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O
Pharmacology
IndicationMay be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Losartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.
Structured Indications
PharmacodynamicsValsartan belongs to a class of antihypertensive agents called angiotensin II receptor blockers (ARBs). Valsartan is a specific and selective type-1 angiotensin II receptor (AT1) antagonist which blocks the blood pressure increasing effects angiotensin II via the renin-angiotensin-aldosterone system (RAAS). RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from granular cells of the juxtaglomerular apparatus in the kidneys. Renin cleaves circulating angiotensinogen to angiotensin I, which is cleaved by angiotensin converting enzyme (ACE) to angiotensin II. Angiotensin II increases blood pressure by increasing total peripheral resistance, increasing sodium and water reabsorption in the kidneys via aldosterone secretion, and altering cardiovascular structure. Angiotensin II binds to two receptors: AT1 and type-2 angiotensin II receptor (AT2). AT1 is a G-protein coupled receptor (GPCR) that mediates the vasoconstrictive and aldosterone-secreting effects of angiotensin II. Studies performed in recent years suggest that AT2 antagonizes AT1-mediated effects and directly affects long-term blood pressure control by inducing vasorelaxation and increasing urinary sodium excretion. Angiotensin receptor blockers (ARBs) are non-peptide competitive inhibitors of AT1. ARBs block the ability of angiotensin II to stimulate pressor and cell proliferative effects. Unlike ACE inhibitors, ARBs do not affect bradykinin-induced vasodilation. The overall effect of ARBs is a decrease in blood pressure.
Mechanism of actionValsartan is an ARB that selectively inhibits the binding of angiotensin II to AT1, which is found in many tissues such as vascular smooth muscle and the adrenal glands. This effectively inhibits the AT1-mediated vasoconstrictive and aldosterone-secreting effects of angiotensin II and results in a decrease in vascular resistance and blood pressure. Valsartan is selective for AT1 and has virtually no affinity for AT2. Inhibition of aldosterone secretion may inhibit sodium and water reabsorption in the kidneys while decreasing potassium excretion. The primary metabolite of valsartan, valeryl 4-hydroxy valsartan, has no pharmacological activity.
TargetKindPharmacological actionActionsOrganismUniProt ID
Type-1 angiotensin II receptorProteinyes
antagonist
HumanP30556 details
Related Articles
AbsorptionAbsolute bioavailability = 23% with high variability
Volume of distribution
  • 17 L (low tissue distribution)
Protein binding94 - 97% bound to serum proteins, primarily serum albumin
Metabolism

Valsartan is excreted largely as unchanged drug (80%) and is minimally metabolized in humans. The primary circulating metabolite, 4-OH-valsartan, is pharmacologically inactive and produced CYP2C9. 4-OH-valsartan accounts for approximately 9% of the circulating dose of valsartan. Although valsartan is metabolized by CYP2C9, CYP-mediated drug-drug interactions between valsartan and other drugs is unlikely.

SubstrateEnzymesProduct
Valsartan
4-HydroxyvalsartanDetails
Route of elimination83% of absorbed valsartan is excreted in feces and 13% is excreted in urine, primarily as unchanged drug
Half lifeThe initial phase t1/2 α is < 1 hour while the terminal phase t1/2 β is 5-9 hours.
Clearance
  • 2 L/h [IV administration]
  • 4.5 L/h [heart Failure patients receiving oral administration 40 to 160 mg twice a day]
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Valsartan Action PathwayDrug actionSMP00165
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Valsartan.Experimental
AbirateroneThe metabolism of Valsartan can be decreased when combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Valsartan is combined with Acebutolol.Approved
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Valsartan.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Valsartan.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Valsartan.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Valsartan is combined with Acetazolamide.Approved, Vet Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Valsartan is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be decreased when combined with Valsartan.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Valsartan is combined with Adapalene.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Valsartan.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Valsartan.Approved, Investigational
AliskirenAliskiren may increase the hyperkalemic activities of Valsartan.Approved, Investigational
AlosetronThe metabolism of Alosetron can be decreased when combined with Valsartan.Approved, Withdrawn
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Valsartan.Approved, Illicit, Investigational
AlprenololValsartan may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanValsartan may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineValsartan may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Valsartan is combined with Amiloride.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Valsartan.Approved, Withdrawn
AmiodaroneThe metabolism of Valsartan can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Valsartan.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Valsartan is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Valsartan.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Valsartan is combined with Amphotericin B.Approved, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Valsartan.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Valsartan is combined with Amyl Nitrite.Approved
AnisodamineThe risk or severity of adverse effects can be increased when Valsartan is combined with Anisodamine.Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Valsartan.Approved
ApixabanThe metabolism of Apixaban can be decreased when combined with Valsartan.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Valsartan is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Valsartan is combined with Apraclonidine.Approved
ApremilastThe risk or severity of adverse effects can be increased when Valsartan is combined with Apremilast.Approved, Investigational
AprepitantThe metabolism of Valsartan can be increased when combined with Aprepitant.Approved, Investigational
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Valsartan.Experimental
ArdeparinArdeparin may increase the hyperkalemic activities of Valsartan.Approved, Withdrawn
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Valsartan.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Valsartan.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Valsartan is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Valsartan is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Valsartan.Approved
AtazanavirThe metabolism of Atazanavir can be decreased when combined with Valsartan.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Valsartan is combined with Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Valsartan is combined with Azapropazone.Withdrawn
AzelastineThe metabolism of Azelastine can be decreased when combined with Valsartan.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Valsartan is combined with Azilsartan medoxomil.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Valsartan is combined with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Valsartan.Experimental
BarbitalBarbital may increase the hypotensive activities of Valsartan.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Valsartan is combined with Barnidipine.Approved
BemiparinBemiparin may increase the hyperkalemic activities of Valsartan.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Valsartan is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Valsartan is combined with Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Valsartan.Withdrawn
BenoxaprofenThe risk or severity of adverse effects can be increased when Valsartan is combined with Benoxaprofen.Withdrawn
BepridilValsartan may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Valsartan is combined with Betaxolol.Approved
BethanidineValsartan may increase the hypotensive activities of Bethanidine.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Valsartan is combined with Betulinic Acid.Investigational
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Valsartan.Approved, Investigational
BimatoprostValsartan may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Valsartan is combined with Bisoprolol.Approved
BortezomibThe metabolism of Bortezomib can be decreased when combined with Valsartan.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Valsartan.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Valsartan is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Valsartan is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Valsartan.Approved
BromfenacThe risk or severity of adverse effects can be increased when Valsartan is combined with Bromfenac.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Valsartan is combined with Bromocriptine.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Valsartan.Approved
BucillamineThe risk or severity of adverse effects can be increased when Valsartan is combined with Bucillamine.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Valsartan is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Valsartan is combined with Bupivacaine.Approved, Investigational
BupranololValsartan may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Valsartan.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Valsartan.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Valsartan.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Valsartan.Approved
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Valsartan.Approved
CandesartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Candesartan.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Valsartan is combined with Candoxatril.Experimental
CapecitabineThe metabolism of Valsartan can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Valsartan is combined with Captopril.Approved
CarbamazepineThe metabolism of Valsartan can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Valsartan is combined with Carbetocin.Approved
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Valsartan.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Valsartan.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Valsartan is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Valsartan is combined with Carteolol.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Valsartan.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Valsartan is combined with Castanospermine.Experimental
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Valsartan.Approved, Investigational
CeliprololValsartan may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Valsartan can be increased when it is combined with Ceritinib.Approved
CertoparinCertoparin may increase the hyperkalemic activities of Valsartan.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Valsartan is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Valsartan is combined with Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Valsartan is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Valsartan.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Valsartan is combined with Chlorthalidone.Approved
CholecalciferolThe metabolism of Valsartan can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilazaprilThe risk or severity of adverse effects can be increased when Valsartan is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Valsartan is combined with Cilnidipine.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Valsartan.Approved
CiprofloxacinValsartan may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Valsartan.Approved, Investigational, Withdrawn
ClevidipineThe risk or severity of adverse effects can be increased when Valsartan is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Valsartan is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Valsartan is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Valsartan is combined with Clonidine.Approved
ClonixinThe risk or severity of adverse effects can be increased when Valsartan is combined with Clonixin.Approved
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Valsartan.Approved, Nutraceutical
ClotrimazoleThe metabolism of Valsartan can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Clozapine can be decreased when combined with Valsartan.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Valsartan is combined with Conivaptan.Approved, Investigational
CryptenamineValsartan may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe risk or severity of adverse effects can be increased when Valsartan is combined with Curcumin.Investigational
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Valsartan.Approved, Investigational
CyclosporineThe metabolism of Valsartan can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineValsartan may increase the hyperkalemic activities of Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideValsartan may increase the hypotensive activities of Cyclothiazide.Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Valsartan is combined with D-Limonene.Investigational
DabrafenibThe serum concentration of Valsartan can be decreased when it is combined with Dabrafenib.Approved
DalteparinDalteparin may increase the hyperkalemic activities of Valsartan.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Valsartan is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Valsartan.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Valsartan.Approved, Investigational
DebrisoquinValsartan may increase the hypotensive activities of Debrisoquin.Approved
DelavirdineThe metabolism of Valsartan can be decreased when combined with Delavirdine.Approved
DeserpidineValsartan may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Valsartan is combined with Desflurane.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Valsartan is combined with Dexmedetomidine.Approved, Vet Approved
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Valsartan.Approved
DiazepamThe metabolism of Diazepam can be decreased when combined with Valsartan.Approved, Illicit, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Valsartan.Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Valsartan.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Valsartan is combined with Diclofenamide.Approved
DicoumarolThe metabolism of Dicoumarol can be decreased when combined with Valsartan.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Valsartan is combined with Diflunisal.Approved
DihydralazineValsartan may increase the hypotensive activities of Dihydralazine.Investigational
DiltiazemThe risk or severity of adverse effects can be increased when Valsartan is combined with Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Valsartan is combined with Dinutuximab.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Valsartan.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Valsartan is combined with Dipyridamole.Approved
DolasetronThe metabolism of Dolasetron can be decreased when combined with Valsartan.Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Valsartan.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Valsartan.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Valsartan.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Valsartan is combined with Doxazosin.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Valsartan.Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Valsartan.Approved, Illicit
DrospirenoneValsartan may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Valsartan is combined with Droxicam.Approved
DuloxetineValsartan may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Valsartan is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Valsartan is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Valsartan is combined with Ebselen.Investigational
EfavirenzThe metabolism of Valsartan can be decreased when combined with Efavirenz.Approved, Investigational
EfonidipineValsartan may increase the hypotensive activities of Efonidipine.Approved
EletriptanThe metabolism of Eletriptan can be decreased when combined with Valsartan.Approved, Investigational
EltrombopagThe serum concentration of Valsartan can be increased when it is combined with Eltrombopag.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Valsartan is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Valsartan is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Valsartan is combined with Enalaprilat.Approved
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Valsartan.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Valsartan is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Valsartan.Approved
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Valsartan.Approved
EprosartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Eprosartan.Approved
EsmololThe risk or severity of adverse effects can be increased when Valsartan is combined with Esmolol.Approved
EstradiolThe metabolism of Estradiol can be decreased when combined with Valsartan.Approved, Investigational, Vet Approved
EstroneThe metabolism of Estrone can be decreased when combined with Valsartan.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Valsartan.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Valsartan is combined with Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Valsartan is combined with Etanercept.Approved, Investigational
EtodolacThe metabolism of Etodolac can be decreased when combined with Valsartan.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Valsartan is combined with Etofenamate.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Valsartan.Approved, Investigational
EtravirineThe metabolism of Etravirine can be decreased when combined with Valsartan.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Valsartan is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when Valsartan is combined with exisulind.Investigational
FelodipineThe risk or severity of adverse effects can be increased when Valsartan is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Valsartan is combined with Fenbufen.Approved
FenoldopamValsartan may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Valsartan is combined with Fenoprofen.Approved
FimasartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Fimasartan.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Valsartan is combined with Floctafenine.Approved, Withdrawn
FloxuridineThe metabolism of Valsartan can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Valsartan can be decreased when combined with Fluconazole.Approved
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Valsartan.Approved
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Valsartan.Approved, Illicit
FlunixinThe risk or severity of adverse effects can be increased when Valsartan is combined with Flunixin.Vet Approved
FluorouracilThe metabolism of Valsartan can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Valsartan.Approved, Vet Approved
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Valsartan.Approved, Investigational
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Valsartan.Approved
FluvoxamineThe metabolism of Valsartan can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Valsartan.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Valsartan is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Valsartan can be increased when combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Valsartan.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Valsartan is combined with Furosemide.Approved, Vet Approved
GavestinelThe metabolism of Gavestinel can be decreased when combined with Valsartan.Investigational
GemfibrozilThe metabolism of Valsartan can be decreased when combined with Gemfibrozil.Approved
GliclazideThe metabolism of Gliclazide can be decreased when combined with Valsartan.Approved
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Valsartan.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Valsartan.Approved
GlyburideThe metabolism of Glyburide can be decreased when combined with Valsartan.Approved
GuanabenzValsartan may increase the hypotensive activities of Guanabenz.Approved
GuanadrelValsartan may increase the hypotensive activities of Guanadrel.Approved
GuanethidineValsartan may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Valsartan is combined with Guanfacine.Approved, Investigational
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Valsartan.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Valsartan.Approved, Vet Approved
HeparinHeparin may increase the hyperkalemic activities of Valsartan.Approved, Investigational
HexamethoniumValsartan may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Valsartan.Approved
HigenamineThe risk or severity of adverse effects can be increased when Valsartan is combined with Higenamine.Investigational
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Valsartan.Approved
HMPL-004The risk or severity of adverse effects can be increased when Valsartan is combined with HMPL-004.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Valsartan.Approved
HydralazineThe risk or severity of adverse effects can be increased when Valsartan is combined with Hydralazine.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Valsartan.Approved, Vet Approved
HydroflumethiazideValsartan may increase the hypotensive activities of Hydroflumethiazide.Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Valsartan.Approved, Illicit
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Valsartan.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Valsartan is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Valsartan is combined with Icatibant.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Valsartan.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Valsartan.Approved
IloprostIloprost may increase the hypotensive activities of Valsartan.Approved, Investigational
ImatinibThe metabolism of Imatinib can be decreased when combined with Valsartan.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Valsartan is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Valsartan is combined with Imipramine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Valsartan is combined with Indapamide.Approved
IndenololValsartan may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Valsartan can be decreased when combined with Indinavir.Approved
indisulamThe metabolism of indisulam can be decreased when combined with Valsartan.Investigational
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Valsartan.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Valsartan is combined with Indoprofen.Withdrawn
IndoraminValsartan may increase the hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Valsartan.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Valsartan.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Valsartan.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Valsartan is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Valsartan is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Valsartan is combined with Isosorbide Mononitrate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Valsartan is combined with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Valsartan is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Valsartan is combined with Isradipine.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Valsartan.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Valsartan is combined with Kebuzone.Experimental
KetamineThe metabolism of Ketamine can be decreased when combined with Valsartan.Approved, Vet Approved
KetanserinValsartan may increase the hypotensive activities of Ketanserin.Investigational
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Valsartan.Approved
KetoconazoleThe metabolism of Valsartan can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Valsartan.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Valsartan is combined with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Valsartan is combined with Labetalol.Approved
LacidipineValsartan may increase the hypotensive activities of Lacidipine.Approved
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Valsartan.Approved, Investigational
LatanoprostValsartan may increase the hypotensive activities of Latanoprost.Approved, Investigational
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Valsartan.Approved, Investigational
LercanidipineValsartan may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LesinuradThe metabolism of Lesinurad can be decreased when combined with Valsartan.Approved
LevobunololThe risk or severity of adverse effects can be increased when Valsartan is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Valsartan is combined with Levobupivacaine.Approved
LevodopaValsartan may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Valsartan is combined with Levosimendan.Approved, Investigational
LicofeloneThe metabolism of Licofelone can be decreased when combined with Valsartan.Investigational
LidocaineThe metabolism of Lidocaine can be decreased when combined with Valsartan.Approved, Vet Approved
LisinoprilThe risk or severity of adverse effects can be increased when Valsartan is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Valsartan is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Valsartan.Approved
LofexidineValsartan may increase the hypotensive activities of Lofexidine.Approved, Investigational
LoratadineThe metabolism of Loratadine can be decreased when combined with Valsartan.Approved
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Valsartan.Approved
LosartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Losartan.Approved
LovastatinThe metabolism of Valsartan can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Valsartan is combined with Loxoprofen.Approved
LumacaftorThe serum concentration of Valsartan can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Valsartan.Approved, Investigational
MacitentanValsartan may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Valsartan is combined with Magnesium salicylate.Approved
ManidipineValsartan may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Valsartan is combined with Mannitol.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Valsartan is combined with Masoprocol.Approved
MebanazineMebanazine may increase the hypotensive activities of Valsartan.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Valsartan is combined with Mecamylamine.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Valsartan is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Valsartan.Approved
MelatoninThe metabolism of Melatonin can be decreased when combined with Valsartan.Approved, Nutraceutical, Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Valsartan.Approved, Vet Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Valsartan.Investigational, Withdrawn
MesalazineThe risk or severity of adverse effects can be increased when Valsartan is combined with Mesalazine.Approved
MestranolThe metabolism of Mestranol can be decreased when combined with Valsartan.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Valsartan is combined with Metamizole.Withdrawn
MethadoneThe metabolism of Methadone can be decreased when combined with Valsartan.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Valsartan is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Valsartan.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Valsartan.Approved, Vet Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Valsartan is combined with Methyclothiazide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Valsartan is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Valsartan.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Valsartan.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Valsartan.Approved
MetipranololThe risk or severity of adverse effects can be increased when Valsartan is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Valsartan is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Valsartan is combined with Metoprolol.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Valsartan.Approved
MetyrosineValsartan may increase the hypotensive activities of Metyrosine.Approved
MibefradilValsartan may increase the hypotensive activities of Mibefradil.Withdrawn
MifepristoneThe serum concentration of Valsartan can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Valsartan.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Valsartan is combined with Minoxidil.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Valsartan.Approved
MizoribineThe risk or severity of adverse effects can be increased when Valsartan is combined with Mizoribine.Investigational
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Valsartan.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Valsartan is combined with Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Valsartan.Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Valsartan.Approved
MorphineThe risk or severity of adverse effects can be increased when Valsartan is combined with Morphine.Approved, Investigational
MoxonidineValsartan may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Valsartan is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Valsartan is combined with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Valsartan is combined with Nabilone.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Valsartan is combined with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Valsartan is combined with Nadolol.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Valsartan.Approved
NafamostatThe risk or severity of adverse effects can be increased when Valsartan is combined with Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Valsartan is combined with Naftifine.Approved
NaftopidilValsartan may increase the hypotensive activities of Naftopidil.Investigational
NaproxenThe metabolism of Naproxen can be decreased when combined with Valsartan.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Valsartan.Approved, Investigational
NCX 4016The risk or severity of adverse effects can be increased when Valsartan is combined with NCX 4016.Investigational
NebivololThe risk or severity of adverse effects can be increased when Valsartan is combined with Nebivolol.Approved, Investigational
NepafenacThe risk or severity of adverse effects can be increased when Valsartan is combined with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Valsartan is combined with Nesiritide.Approved, Investigational
NetupitantThe metabolism of Netupitant can be decreased when combined with Valsartan.Approved
NevirapineThe metabolism of Nevirapine can be decreased when combined with Valsartan.Approved
NialamideNialamide may increase the hypotensive activities of Valsartan.Withdrawn
NicardipineThe metabolism of Valsartan can be decreased when combined with Nicardipine.Approved
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Valsartan.Approved, Vet Approved
NicorandilNicorandil may increase the hypotensive activities of Valsartan.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Valsartan.Approved
NifedipineThe risk or severity of adverse effects can be increased when Valsartan is combined with Nifedipine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Valsartan is combined with Niflumic Acid.Approved
NiguldipineValsartan may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineValsartan may increase the hypotensive activities of Nilvadipine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Valsartan is combined with Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Valsartan is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Valsartan is combined with Nisoldipine.Approved
NitrendipineValsartan may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Valsartan is combined with Nitric Oxide.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Valsartan is combined with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Valsartan is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Valsartan is combined with Nitroprusside.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Valsartan.Approved
ObinutuzumabValsartan may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Valsartan.Withdrawn
OlmesartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Olmesartan.Approved, Investigational
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Valsartan.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Valsartan is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Valsartan is combined with Olsalazine.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Valsartan is combined with Omapatrilat.Investigational
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Valsartan.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Valsartan.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Valsartan is combined with Orgotein.Vet Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Valsartan.Approved
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Valsartan.Approved
OxprenololValsartan may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Valsartan is combined with Oxyphenbutazone.Withdrawn
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Valsartan.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Valsartan is combined with Papaverine.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Valsartan.Approved
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Valsartan.Approved
PargylinePargyline may increase the hypotensive activities of Valsartan.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Valsartan.Approved
PenbutololThe risk or severity of adverse effects can be increased when Valsartan is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Valsartan.Approved, Vet Approved
PentoliniumValsartan may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Valsartan.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Valsartan is combined with Perindopril.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Valsartan.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Valsartan.Withdrawn
PhenelzinePhenelzine may increase the hypotensive activities of Valsartan.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Valsartan.Withdrawn
PhenobarbitalThe metabolism of Valsartan can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineValsartan may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Valsartan.Withdrawn
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Valsartan.Approved
PhentolamineValsartan may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Valsartan.Approved, Vet Approved
PhenytoinThe metabolism of Valsartan can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Valsartan is combined with Pimecrolimus.Approved, Investigational
PinacidilValsartan may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Valsartan is combined with Pindolol.Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Valsartan.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Valsartan is combined with Pipamperone.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Valsartan is combined with Pirfenidone.Investigational
PirlindolePirlindole may increase the hypotensive activities of Valsartan.Approved
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Valsartan.Approved, Investigational
PitavastatinThe metabolism of Pitavastatin can be decreased when combined with Valsartan.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Valsartan.Withdrawn
PolythiazideValsartan may increase the hypotensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Valsartan is combined with Pramipexole.Approved, Investigational
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Valsartan.Approved
PravastatinThe metabolism of Pravastatin can be decreased when combined with Valsartan.Approved
PrazosinThe risk or severity of adverse effects can be increased when Valsartan is combined with Prazosin.Approved
PrimidoneThe metabolism of Valsartan can be increased when combined with Primidone.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Valsartan.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Valsartan.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Valsartan.Approved, Vet Approved
PropacetamolThe risk or severity of adverse effects can be increased when Valsartan is combined with Propacetamol.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Valsartan.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Valsartan is combined with Propranolol.Approved, Investigational
PTC299The risk or severity of adverse effects can be increased when Valsartan is combined with PTC299.Investigational
PyrimethamineThe metabolism of Valsartan can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Valsartan.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Valsartan is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Valsartan is combined with Quinapril.Approved, Investigational
QuinidineThe metabolism of Quinidine can be decreased when combined with Valsartan.Approved
QuinineQuinine may increase the hypotensive activities of Valsartan.Approved
RamiprilThe risk or severity of adverse effects can be increased when Valsartan is combined with Ramipril.Approved
RasagilineRasagiline may increase the hypotensive activities of Valsartan.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Valsartan is combined with Remifentanil.Approved
RemikirenValsartan may increase the hypotensive activities of Remikiren.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Valsartan is combined with Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Valsartan is combined with Reserpine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Valsartan is combined with Resveratrol.Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Valsartan.Approved
RifampicinThe metabolism of Valsartan can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Valsartan can be increased when combined with Rifapentine.Approved
RilmenidineValsartan may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Valsartan is combined with Riociguat.Approved
RisperidoneValsartan may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabValsartan may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Valsartan.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Valsartan is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Valsartan is combined with Ropivacaine.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Valsartan.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Valsartan.Approved
RotigotineThe risk or severity of adverse effects can be increased when Valsartan is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Valsartan is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Valsartan.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Valsartan is combined with Salicylamide.Approved
Salicylic acidThe metabolism of Salicylic acid can be decreased when combined with Valsartan.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Valsartan is combined with Salsalate.Approved
SaprisartanValsartan may increase the hypotensive activities of Saprisartan.Experimental
SecobarbitalThe metabolism of Valsartan can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Valsartan.Approved, Investigational, Vet Approved
SelexipagValsartan may increase the hypotensive activities of Selexipag.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Valsartan.Approved, Investigational
SertralineThe metabolism of Sertraline can be decreased when combined with Valsartan.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Valsartan is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Valsartan.Approved, Investigational
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Valsartan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Valsartan is combined with Sodium Nitrite.Approved
SorafenibThe metabolism of Valsartan can be decreased when combined with Sorafenib.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Valsartan is combined with Sotalol.Approved
SpiraprilThe risk or severity of adverse effects can be increased when Valsartan is combined with Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Valsartan is combined with Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Valsartan is combined with SRT501.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Valsartan is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Valsartan is combined with Sufentanil.Approved, Investigational
SulfadiazineThe metabolism of Valsartan can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Valsartan.Approved
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Valsartan.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Valsartan is combined with Sulfasalazine.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Valsartan.Approved
SulfisoxazoleThe metabolism of Valsartan can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Valsartan is combined with Sulindac.Approved
SuprofenThe metabolism of Suprofen can be decreased when combined with Valsartan.Approved, Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Valsartan.Approved, Investigational
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Valsartan.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Valsartan is combined with Tamsulosin.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Valsartan.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Telmisartan.Approved, Investigational
TemazepamThe metabolism of Temazepam can be decreased when combined with Valsartan.Approved
TemocaprilThe risk or severity of adverse effects can be increased when Valsartan is combined with Temocapril.Experimental, Investigational
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Valsartan.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Valsartan is combined with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Valsartan is combined with Terazosin.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Valsartan.Approved, Investigational, Vet Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Valsartan.Withdrawn
TeriflunomideThe serum concentration of Valsartan can be increased when it is combined with Teriflunomide.Approved
TerlipressinValsartan may increase the hypotensive activities of Terlipressin.Approved, Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Valsartan.Approved, Investigational
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Valsartan.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Valsartan.Approved
ThiamylalThe metabolism of Thiamylal can be decreased when combined with Valsartan.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Valsartan.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Valsartan is combined with Thioridazine.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Valsartan is combined with Tiaprofenic acid.Approved
TiboloneValsartan may increase the hypotensive activities of Tibolone.Approved
TicagrelorThe metabolism of Valsartan can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Valsartan can be decreased when combined with Ticlopidine.Approved
TicrynafenValsartan may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Valsartan is combined with Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Valsartan is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Valsartan.Approved
TizanidineThe risk or severity of adverse effects can be increased when Valsartan is combined with Tizanidine.Approved
TolazolineValsartan may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideThe metabolism of Valsartan can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Valsartan is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Valsartan is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Valsartan is combined with Tolmetin.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Valsartan.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Valsartan.Approved, Investigational
TolvaptanTolvaptan may increase the hyperkalemic activities of Valsartan.Approved
TorasemideThe risk or severity of adverse effects can be increased when Valsartan is combined with Torasemide.Approved
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Valsartan.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Valsartan is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Valsartan is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Valsartan.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Valsartan.Approved
TravoprostValsartan may increase the hypotensive activities of Travoprost.Approved
TreprostinilThe metabolism of Treprostinil can be decreased when combined with Valsartan.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Valsartan.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Valsartan is combined with Triamterene.Approved
TrichlormethiazideValsartan may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinValsartan may increase the hypotensive activities of Trimazosin.Experimental
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Valsartan.Approved
TrimethaphanValsartan may increase the hypotensive activities of Trimethaphan.Approved
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Valsartan.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Valsartan.Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Valsartan is combined with Trisalicylate-choline.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Valsartan.Withdrawn
UdenafilUdenafil may increase the antihypertensive activities of Valsartan.Approved, Investigational
UnoprostoneValsartan may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Valsartan.Investigational, Withdrawn
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Valsartan.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Valsartan.Approved
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Valsartan.Approved
VerapamilThe risk or severity of adverse effects can be increased when Valsartan is combined with Verapamil.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Valsartan.Investigational
VinpocetineValsartan may increase the hypotensive activities of Vinpocetine.Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Valsartan.Approved
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Valsartan.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Valsartan.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Valsartan.Approved
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Valsartan.Approved, Investigational, Withdrawn
XylometazolineValsartan may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Valsartan.Approved, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Valsartan.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Valsartan.Approved
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Valsartan.Approved
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Valsartan.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Valsartan.Approved, Investigational, Withdrawn
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Valsartan.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Valsartan is combined with Zomepirac.Withdrawn
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Valsartan.Approved
Food InteractionsNot Available
References
Synthesis Reference

Zvi Harel, Igor Rukhman, “Process for the preparation of valsartan.” U.S. Patent US20050010053, issued January 13, 2005.

US20050010053
General References
  1. Bader, M. (2004). Renin-angiotensin-aldosterone system. In Encyclopedic reference of molecular pharmacology (pp. 810-814). Berlin: Springer. [ISBN:9783540298328 ]
External Links
ATC CodesC10BX10C09DX02C09DB08C09DB01C09DX01C09DA03C09DX04C09CA03
AHFS Codes
  • 24:32.08
PDB EntriesNot Available
FDA labelDownload (237 KB)
MSDSDownload (36.2 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9956
Blood Brain Barrier-0.8032
Caco-2 permeable-0.6912
P-glycoprotein substrateSubstrate0.685
P-glycoprotein inhibitor INon-inhibitor0.5548
P-glycoprotein inhibitor IINon-inhibitor0.5966
Renal organic cation transporterNon-inhibitor0.8646
CYP450 2C9 substrateNon-substrate0.7722
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5073
CYP450 1A2 substrateNon-inhibitor0.8707
CYP450 2C9 inhibitorNon-inhibitor0.5398
CYP450 2D6 inhibitorNon-inhibitor0.8816
CYP450 2C19 inhibitorInhibitor0.5539
CYP450 3A4 inhibitorNon-inhibitor0.5521
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5618
Ames testNon AMES toxic0.6384
CarcinogenicityNon-carcinogens0.645
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6518 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9766
hERG inhibition (predictor II)Non-inhibitor0.7388
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Novartis pharmaceuticals corp
  • Novartis Corporation
Packagers
Dosage forms
FormRouteStrength
TabletOral
TabletOral320 mg
TabletOral40 mg
CapsuleOral160 mg
TabletOral160 mg
CapsuleOral80 mg
TabletOral80 mg
Tablet, film coatedOral
TabletOral160 mg/1
TabletOral320 mg/1
TabletOral40 mg/1
TabletOral80 mg/1
Tablet, film coatedOral160 mg/1
Tablet, film coatedOral320 mg/1
Tablet, film coatedOral40 mg/1
Tablet, film coatedOral80 mg/1
Prices
Unit descriptionCostUnit
Diovan hct 320-25 mg tablet4.63USD tablet
Diovan hct 320-12.5 mg tablet4.1USD tablet
Diovan hct 160-25 mg tablet3.66USD tablet
Diovan hct 160-12.5 mg tablet3.27USD tablet
Diovan 320 mg tablet3.17USD tablet
Diovan hct 80-12.5 mg tablet3.0USD tablet
Diovan 160 mg tablet2.42USD tablet
Diovan 80 mg tablet2.33USD tablet
Diovan 40 mg tablet2.32USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2036427 No1998-12-292011-02-15Canada
CA2259148 No2009-09-292017-06-18Canada
US5399578 No1995-03-212012-03-21Us
US5559111 No1998-07-212018-07-21Us
US5972990 Yes1997-04-262017-04-26Us
US6294197 Yes1997-12-182017-12-18Us
US6395728 No1999-07-082019-07-08Us
US7468390 No2003-11-272023-11-27Us
US8101599 No2003-05-162023-05-16Us
US8101659 No2003-01-142023-01-14Us
US8168616 No2006-07-032026-07-03Us
US8404744 No2003-01-142023-01-14Us
US8475839 Yes2003-11-162023-11-16Us
US8796331 No2003-01-142023-01-14Us
US8877938 No2007-05-272027-05-27Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point116-117 °CNot Available
logP5.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0234 mg/mLALOGPS
logP3.68ALOGPS
logP5.27ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)4.37ChemAxon
pKa (Strongest Basic)-0.11ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area112.07 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity134.77 m3·mol-1ChemAxon
Polarizability47.27 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as biphenyltetrazoles and derivatives. These are organic compounds containing a biphenyl attached to a tetrazole. A carbon atom of the biphenyl moiety is boned to a carbon or the nitrogen atom of the tetrazole moiety.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzoles
Sub ClassTetrazoles
Direct ParentBiphenyltetrazoles and derivatives
Alternative Parents
Substituents
  • Biphenyltetrazole
  • N-acyl-aliphatic-alpha amino acid
  • N-acyl-alpha amino acid or derivatives
  • N-acyl-alpha-amino acid
  • Biphenyl
  • N-acyl-l-alpha-amino acid
  • Alpha-amino acid or derivatives
  • Phenylmethylamine
  • Benzylamine
  • Benzenoid
  • N-acyl-amine
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Tertiary carboxylic acid amide
  • Tertiary amine
  • Carboxamide group
  • Azacycle
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Gene Name:
AGTR1
Uniprot ID:
P30556
Molecular Weight:
41060.53 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Azizi M, Menard J, Bissery A, Guyenne TT, Bura-Riviere A, Vaidyanathan S, Camisasca RP: Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol. 2004 Dec;15(12):3126-33. [PubMed:15579516 ]
  3. Criscione L, de Gasparo M, Buhlmayer P, Whitebread S, Ramjoue HP, Wood J: Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. Br J Pharmacol. 1993 Oct;110(2):761-71. [PubMed:8242249 ]
  4. Shargorodsky M, Leibovitz E, Lubimov L, Gavish D, Zimlichman R: Prolonged treatment with the AT1 receptor blocker, valsartan, increases small and large artery compliance in uncomplicated essential hypertension. Am J Hypertens. 2002 Dec;15(12):1087-91. [PubMed:12460705 ]
  5. de Gasparo M, Whitebread S: Binding of valsartan to mammalian angiotensin AT1 receptors. Regul Pept. 1995 Nov 10;59(3):303-11. [PubMed:8577935 ]
  6. Siragy HM, El-Kersh MA, De Gasparo M, Webb RL, Carey RM: Differences in AT2 -receptor stimulation between AT1 -receptor blockers valsartan and losartan quantified by renal interstitial fluid cGMP. J Hypertens. 2002 Jun;20(6):1157-63. [PubMed:12023686 ]
  7. Stanfield, Cindy L.;Germann, William J. (2009). Principles of Human Physiology (3rd ed.). Benjamin-Cummings Publishing Company. [ISBN:978-0321556660 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Nakashima A, Kawashita H, Masuda N, Saxer C, Niina M, Nagae Y, Iwasaki K: Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes. Xenobiotica. 2005 Jun;35(6):589-602. [PubMed:16192110 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP). Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B3
Uniprot ID:
Q9NPD5
Molecular Weight:
77402.175 Da
References
  1. Poirier A, Cascais AC, Funk C, Lave T: Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data. J Pharmacokinet Pharmacodyn. 2009 Dec;36(6):585-611. doi: 10.1007/s10928-009-9139-3. Epub 2009 Nov 20. [PubMed:19936896 ]
  2. Poirier A, Cascais AC, Funk C, Lave T: Prediction of pharmacokinetic profile of valsartan in humans based on in vitro uptake-transport data. Chem Biodivers. 2009 Nov;6(11):1975-87. doi: 10.1002/cbdv.200900116. [PubMed:19937834 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Molecular Weight:
76447.99 Da
References
  1. Poirier A, Cascais AC, Funk C, Lave T: Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data. J Pharmacokinet Pharmacodyn. 2009 Dec;36(6):585-611. doi: 10.1007/s10928-009-9139-3. Epub 2009 Nov 20. [PubMed:19936896 ]
  2. Poirier A, Cascais AC, Funk C, Lave T: Prediction of pharmacokinetic profile of valsartan in humans based on in vitro uptake-transport data. Chem Biodivers. 2009 Nov;6(11):1975-87. doi: 10.1002/cbdv.200900116. [PubMed:19937834 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 02, 2016 03:58